GEN Exclusives

More »

GEN News Highlights

More »
Nov 20, 2006

Artemis and Merck & Co to Generate Genetically Engineered In-Vivo RNAi Mouse Models

  • Artemis Pharmaceuticals signed a research agreement with Merck & Co. to construct a large number of shRNAi-genetically engineered mouse models for the in vivo functional analysis of selected disease-related genes. The agreement represents a significant initiative to undertake a large-scale approach to gene-function analysis using shRNA knock down in genetically engineered mice as models for human biology.

    Under the terms of the agreement, Artemis will generate genetically engineered shRNAi knock-down mouse models for Merck using its vector construction, ES cell transfection, and inducible RNAi technology. Merck will provide selected shRNA sequences that correspond to mouse genes that may also play a central role in human diseases. Artemis will use its technologies to achieve constitutive as well as inducible functional down-regulation of the expression of the gene targets provided by Merck.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?